| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EFNA3 |
| Uniprot No | P52797 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-211aa |
| 氨基酸序列 | QGPGGALGNRHAVYWNSSNQHLRREGYTVQVNVNDYLDIYCPHYNSSGVG PGAGPGPGGGAEQYVLYMVSRNGYRTCNASQGFKRWECNRPHAPHSPIKF SEKFQRYSAFSLGYEFHAGHEYYYISTPTHNLHWKCLRMKVFVCCASTSH SGEKPVPTLPQFTMGPNVKINVLEDFEGENPQVPKLEKSVDHHHHHH |
| 预测分子量 | 22 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于EFNA3重组蛋白的3篇参考文献示例(内容为虚构，仅供格式参考)：
1. **文献名称**：*Recombinant Ephrin-A3 Promotes Angiogenesis via Eph Receptor Activation in Endothelial Cells*
**作者**：Smith J, et al.
**摘要**：研究通过表达并纯化EFNA3重组蛋白，证实其与EphA4受体结合后可激活下游信号通路，促进内皮细胞迁移和血管新生，为缺血性疾病治疗提供潜在靶点。
2. **文献名称**：*Structural Characterization of Recombinant EFNA3 and Its Binding Mechanism to Eph Receptors*
**作者**：Chen L, et al.
**摘要**：利用X射线晶体学解析EFNA3重组蛋白的三维结构，揭示其与EphA2受体相互作用的关键表位，为设计靶向Eph-ephrin系统的药物提供结构基础。
3. **文献名称**：*EFNA3 Recombinant Protein Attenuates Neuroinflammation in a Mouse Model of Multiple Sclerosis*
**作者**：Garcia R, et al.
**摘要**：在小鼠模型中，外源性EFNA3重组蛋白通过调控小胶质细胞活性，显著减轻中枢神经系统炎症反应，提示其在神经退行性疾病中的治疗潜力。
(注：以上文献及摘要均为模拟创作，实际文献需通过学术数据库检索。)
**Background of EFNA3 Recombinant Protein**
Ephrin-A3 (EFNA3) is a member of the ephrin family of membrane-bound ligands that interact with Eph receptor tyrosine kinases to mediate bidirectional cell-cell signaling. This ligand-receptor system plays critical roles in developmental processes, including axon guidance, tissue patterning, and angiogenesis, as well as in pathological conditions such as cancer, inflammation, and neurological disorders. EFNA3 is a glycosylphosphatidylinositol (GPI)-anchored protein primarily expressed in the brain, vascular endothelium, and certain epithelial tissues. It binds preferentially to EphA-class receptors (e.g., EphA3. EphA4), triggering signaling cascades that regulate cell adhesion, migration, and spatial organization.
Recombinant EFNA3 protein is engineered to mimic the native ligand's functional properties while enabling controlled experimental use. It is typically produced in mammalian expression systems (e.g., HEK293 or CHO cells) or *E. coli* (as a soluble fragment), depending on the requirement for post-translational modifications. The recombinant form often includes the extracellular receptor-binding domain, purified to high homogeneity for use in *in vitro* or *in vivo* studies. Researchers employ EFNA3 recombinant protein to investigate its role in Eph receptor activation, downstream signaling pathways (e.g., MAPK, PI3K), and its involvement in diseases. For instance, EFNA3 overexpression has been linked to tumor angiogenesis and metastasis, making it a potential therapeutic target.
In drug discovery, EFNA3 recombinant protein serves as a tool for screening inhibitors or antibodies that block EphA-ephrin interactions. Its applications extend to neuronal regeneration studies, where EFNA3-EphA signaling influences synaptic plasticity and repair. Challenges in production include maintaining proper folding and avoiding aggregation, necessitating stringent quality control via techniques like SDS-PAGE, Western blotting, and functional assays (e.g., receptor-binding ELISAs). Overall, EFNA3 recombinant protein is a vital resource for dissecting cell communication mechanisms and developing targeted therapies.
×
